1763 related articles for article (PubMed ID: 32707537)
1. Hazards of the Cytokine Storm and Cytokine-Targeted Therapy in Patients With COVID-19: Review.
Quirch M; Lee J; Rehman S
J Med Internet Res; 2020 Aug; 22(8):e20193. PubMed ID: 32707537
[TBL] [Abstract][Full Text] [Related]
2. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
4. Cytokine storm induced by SARS-CoV-2.
Song P; Li W; Xie J; Hou Y; You C
Clin Chim Acta; 2020 Oct; 509():280-287. PubMed ID: 32531256
[TBL] [Abstract][Full Text] [Related]
5. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
Atluri S; Manchikanti L; Hirsch JA
Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
[TBL] [Abstract][Full Text] [Related]
6. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.
Wang J; Jiang M; Chen X; Montaner LJ
J Leukoc Biol; 2020 Jul; 108(1):17-41. PubMed ID: 32534467
[TBL] [Abstract][Full Text] [Related]
7. Cytokine Storm in COVID-19-Immunopathological Mechanisms, Clinical Considerations, and Therapeutic Approaches: The REPROGRAM Consortium Position Paper.
Bhaskar S; Sinha A; Banach M; Mittoo S; Weissert R; Kass JS; Rajagopal S; Pai AR; Kutty S
Front Immunol; 2020; 11():1648. PubMed ID: 32754159
[TBL] [Abstract][Full Text] [Related]
8. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
[TBL] [Abstract][Full Text] [Related]
9. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs.
Tufan A; Avanoğlu Güler A; Matucci-Cerinic M
Turk J Med Sci; 2020 Apr; 50(SI-1):620-632. PubMed ID: 32299202
[TBL] [Abstract][Full Text] [Related]
10. Treatment of coronavirus disease 2019.
Hung IFN
Curr Opin HIV AIDS; 2020 Nov; 15(6):336-340. PubMed ID: 33002954
[TBL] [Abstract][Full Text] [Related]
11. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
12. Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications.
Pelaia C; Tinello C; Vatrella A; De Sarro G; Pelaia G
Ther Adv Respir Dis; 2020; 14():1753466620933508. PubMed ID: 32539627
[TBL] [Abstract][Full Text] [Related]
13. [Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway].
Ren Y; Yao MC; Huo XQ; Gu Y; Zhu WX; Qiao YJ; Zhang YL
Zhongguo Zhong Yao Za Zhi; 2020 Mar; 45(6):1225-1231. PubMed ID: 32281329
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapeutic approaches to curtail COVID-19.
Owji H; Negahdaripour M; Hajighahramani N
Int Immunopharmacol; 2020 Nov; 88():106924. PubMed ID: 32877828
[TBL] [Abstract][Full Text] [Related]
15. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of "inflame-aging".
Meftahi GH; Jangravi Z; Sahraei H; Bahari Z
Inflamm Res; 2020 Sep; 69(9):825-839. PubMed ID: 32529477
[TBL] [Abstract][Full Text] [Related]
16. Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies.
Tang Y; Liu J; Zhang D; Xu Z; Ji J; Wen C
Front Immunol; 2020; 11():1708. PubMed ID: 32754163
[TBL] [Abstract][Full Text] [Related]
17. Drug repurposing and cytokine management in response to COVID-19: A review.
Heimfarth L; Serafini MR; Martins-Filho PR; Quintans JSS; Quintans-Júnior LJ
Int Immunopharmacol; 2020 Nov; 88():106947. PubMed ID: 32919216
[TBL] [Abstract][Full Text] [Related]
18. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
19. Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19.
Schumann S; Kaiser A; Nicoletti F; Mangano K; Fagone P; van Wijk E; Yan Y; Schulz P; Ludescher B; Niedermaier M; von Wegerer J; Rauch P; Setz C; Schubert U; Brysch W
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233817
[TBL] [Abstract][Full Text] [Related]
20. COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation.
Kempuraj D; Selvakumar GP; Ahmed ME; Raikwar SP; Thangavel R; Khan A; Zaheer SA; Iyer SS; Burton C; James D; Zaheer A
Neuroscientist; 2020; 26(5-6):402-414. PubMed ID: 32684080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
